{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:20:33Z","timestamp":1792704033739,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.anai.2021.07.010","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T01:55:25Z","timestamp":1626314125000},"page":"579-587.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Severe asthma exacerbations in the United States:"],"prefix":"10.1016","volume":"127","author":[{"given":"Jennifer","family":"Trevor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weily","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr,","given":"Reynold A.","family":"Panettieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Trudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0001","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0002","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.anai.2021.07.010_bib0003","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.amjmed.2017.12.034","article-title":"Severe asthma in primary care: identification and management","volume":"131","author":"Trevor","year":"2018","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0004","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaip.2019.11.009","article-title":"Exacerbation-prone asthma","volume":"8","author":"Denlinger","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2021.07.010_bib0005","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201809-1817PP","article-title":"Unmet needs in severe asthma subtyping and precision medicine trials. Bridging clinical and patient perspectives","volume":"199","author":"Siddiqui","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2021.07.010_bib0006","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2012.01.039","article-title":"Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma","volume":"129","author":"Ivanova","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2021.07.010_bib0007","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3109\/02770903.2015.1004683","article-title":"Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation","volume":"52","author":"Sullivan","year":"2015","journal-title":"J Asthma"},{"issue":"4","key":"10.1016\/j.anai.2021.07.010_bib0008","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/ACI.0000000000000284","article-title":"Biologic therapy in the management of asthma","volume":"16","author":"McCracken","year":"2016","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.07.010_bib0009","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.anai.2020.04.004","article-title":"Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma","volume":"125","author":"Moore","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.07.010_bib0010","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from Prospero, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.07.010_bib0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/JAA.S236609","article-title":"Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs","volume":"13","author":"Llanos","year":"2020","journal-title":"J Asthma Allergy"},{"issue":"6","key":"10.1016\/j.anai.2021.07.010_bib0012","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-word experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.07.010_bib0013","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anai.2017.08.016","article-title":"Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma","volume":"120","author":"Tadrous","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.07.010_bib0014","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.anai.2021.07.010_bib0015","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2021.07.010_bib0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.rmed.2016.08.006","article-title":"Predictors of frequent exacerbations in (ex)smoking and never smoking adults with severe asthma","volume":"118","author":"Westerhof","year":"2016","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2021.07.010_bib0017","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"26","key":"10.1016\/j.anai.2021.07.010_bib0018","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.anai.2021.07.010_bib0019","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.rmed.2013.02.018","article-title":"Exhaled nitric oxide to predict corticosteroid responsiveness and reduce asthma exacerbation rates","volume":"107","author":"Donohue","year":"2013","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.anai.2021.07.010_bib0020","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2021.07.010_bib0021","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/13993003.00699-2016","article-title":"Predictive value of exhaled nitric oxide in the management of asthma: a systematic review","volume":"48","author":"Lehtimaki","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2021.07.010_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2018.08.005","article-title":"Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function","volume":"143","author":"Mansur","year":"2018","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0023","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jaip.2013.01.011","article-title":"Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents","volume":"1","author":"Sorkness","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.07.010_bib0024","unstructured":"Global Initiative For Asthma (GINA). Global strategy for asthma management and prevention. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/04\/GINA-2020-full-report_-final-_wms.pdf. Accessed October 20, 2020."},{"issue":"10056","key":"10.1016\/j.anai.2021.07.010_bib0025","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of Benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b2 2-agonists (Sirocco): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0026","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.07.010_bib0027","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.anai.2021.07.010_bib0028","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2021.07.010_bib0029","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2021.07.010_bib0030","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2021.07.010_bib0031","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","article-title":"Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis","volume":"20","author":"Prazma","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2021.07.010_bib0032","first-page":"77","article-title":"The CHRONICLE study of US adults with subspecialist-treated severe asthma: objectives, design, and initial results","volume":"11","author":"Ambrose","year":"2020","journal-title":"Pragmat Obs Res"},{"issue":"3","key":"10.1016\/j.anai.2021.07.010_bib0033","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0034","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaip.2019.08.024","article-title":"Trends and disparities in asthma biologic use in the United States","volume":"8","author":"Inselman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.07.010_bib0035","unstructured":"Institute for Clinical and Economic [Review:2016]. Mepolizumab (Nucala\u00ae, GlaxoSmithKline plc.) for the Treatment of Severe Asthma with Eosinophilia: effectiveness, Value, and Value-Based Price Benchmarks. Available at: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/CTAF_Mepolizumab_Revised_Draft_Report_012516-1.pdf. Accessed October 20, 2020."},{"issue":"13","key":"10.1016\/j.anai.2021.07.010_bib0036","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2021.07.010_bib0037","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"9842","key":"10.1016\/j.anai.2021.07.010_bib0038","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anai.2021.07.010_bib0039","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01444-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"52","author":"Brown","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02187-2018","article-title":"Randomised controlled trials in severe asthma: selection by phenotype or stereotype","volume":"53","author":"Pahus","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2021.07.010_bib0041","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1164\/rccm.200906-0896OC","article-title":"Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program","volume":"181","author":"Moore","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2021.07.010_bib0042","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/02770903.2019.1708095","article-title":"Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study","volume":"58","author":"Mullerova","year":"2021","journal-title":"J Asthma"},{"key":"10.1016\/j.anai.2021.07.010_bib0043","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3389\/fimmu.2018.01416","article-title":"Nonallergic asthma and its severity: biomarkers for its discrimination in peripheral samples","volume":"9","author":"Baos","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.anai.2021.07.010_bib0044","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaip.2014.09.006","article-title":"Asthma phenotypes: nonallergic (intrinsic) asthma","volume":"2","author":"Peters","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.07.010_bib0045","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaci.2012.04.014","article-title":"Key findings and clinical implications from the Epidemiology and Natural History of Asthma: outcomes and Treatment Regimens (TENOR) study","volume":"130","author":"Chipps","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.07.010_bib0046","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/resp.13389","article-title":"Treatable traits can be identified in a severe asthma registry and predict future exacerbations","volume":"24","author":"McDonald","year":"2019","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.anai.2021.07.010_bib0047","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.rmed.2006.07.005","article-title":"Recent asthma exacerbations: a key predictor of future exacerbations","volume":"101","author":"Miller","year":"2007","journal-title":"Respir Med"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621005019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621005019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:26:58Z","timestamp":1761053218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120621005019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1081120621005019"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.07.010","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe asthma exacerbations in the United States:","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}